0001209191-20-037335.txt : 20200617
0001209191-20-037335.hdr.sgml : 20200617
20200617171247
ACCESSION NUMBER: 0001209191-20-037335
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200615
FILED AS OF DATE: 20200617
DATE AS OF CHANGE: 20200617
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fischer Laurent
CENTRAL INDEX KEY: 0001379344
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36579
FILM NUMBER: 20970489
MAIL ADDRESS:
STREET 1: C/O PANACOS PHARMACEUTICALS, INC.
STREET 2: 134 COOLIDGE AVENUE
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adverum Biotechnologies, Inc.
CENTRAL INDEX KEY: 0001501756
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 205258327
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 800 SAGINAW DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-272-6269
MAIL ADDRESS:
STREET 1: 800 SAGINAW DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
FORMER COMPANY:
FORMER CONFORMED NAME: Avalanche Biotechnologies, Inc.
DATE OF NAME CHANGE: 20100921
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-15
0
0001501756
Adverum Biotechnologies, Inc.
ADVM
0001379344
Fischer Laurent
C/O ADVERUM BIOTECHNOLOGIES, INC.
800 SAGINAW DRIVE
REDWOOD CITY
CA
94063
1
1
0
0
CEO and Director
Stock Option (Right to Buy)
23.70
2020-06-15
4
A
0
1200000
0.00
A
2030-06-14
Common Stock
1200000
1200000
D
Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of June 15, 2020 (the "Vesting Commencement Date"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to 24 months of accelerated vesting and a 24-month post-termination exercise period in certain events, and subject to the Reporting Person's continued service with the Issuer on each such vesting date.
Laurent D. Fischer, by /s/ Peter Soparkar, Attorney-in-Fact
2020-06-17